Psoriasis

Medical content

>

Psoriasis

Calcipotriene betamethasone

The calcipotriene betamethasone PAD cream is a cream-based combination of CAL and BDP (CAL 0.005% and BDP 0.064%) based on Poly-Aphron Dispersion (PAD) Technology, which is indicated for the topical treatment of mild-to-moderate psoriasis vulgaris, including scalp psoriasis, in adults.1,2

CAL/BDP PAD Cream – Mechanism of Action

MA-HQ-WYN-2300007​

Relevant publications

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Pinter, A. et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. JEADV 2022; 36, 228–236.

View

Pooled Analysis Demonstrating Superior Patient–Reported Psoriasis Treatment Outcomes for Calcipotriene / Betamethasone Dipropionate Cream Versus Suspension / Gel

Armstrong, AW. et al. Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene/betamethasone dipropionate cream versus suspension/gel. J Drugs Dermatol. 2022;21(3):242-248

View

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

Bewley, A. et al. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. Journal of Dermatological Treatment 2022 DOI: 10.1080/09546634.2022.2116924

View

Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application

Praestegaard, M. et al. Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application. Dermatol Ther (Heidelb) (2022) 12:2217–2231

View

Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp

García, N. et al. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp. Drugs Context. 2023;12:2023-2-8. https://doi.org/10.7573/dic.2023-2-8

View

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Torres T et al. Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review. Dermatol Ther (Heidelb). 2023 Sep 23. doi: 10.1007/s13555-023-01003-0.

View

Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey.

López Estebaranz JL, Kurzen H, Galván J. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. J Dermatolog Treat 2024 Dec; 35(1): 2357618. doi: 10.1080/09546634.2024.2357618.

View

Ongoing studies

PRO-SCALP

Prospective, observational cohort study to assess patient treatment satisfaction, patient-reported outcomes, effectiveness, and safety of a fixed-dose combination of Calcipotriene/Betamethasone dipropionate PAD cream in the treatment of mild-to-moderate plaque psoriasis of the scalp in adults (PRO-SCALP).

Ongoing

  • Study started Jun 2023
  • Study planned end Sep 2024
ADHER-TOP

Evaluation of adherence to treatment with CAL/BDP PAD cream in adult patients with mild-to-moderate body psoriasis with or without scalp involvement: ADHER-TOP study.

Ongoing

  • Study started Jul 2024
  • Study planned end Jul 2025

References: 1. Wynzora® Cream - Summary of product characteristics (SmPC). 2. Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream. J Drugs Dermatol JDD. 2021;20(4):420–5.

Discover more about our medical content
Atopic dermatitis
Onychomycosis
Actinic keratosis

Any questions?

Contact us if you need more information related to Almirall portfolio.

Medical Information

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Pooled Analysis Demonstrating Superior Patient–Reported Psoriasis Treatment Outcomes for Calcipotriene / Betamethasone Dipropionate Cream Versus Suspension / Gel

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application

Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey.

Welcome to almiralldermatologycongress.com

The information provided on this website is intended for use by healthcare professionals qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.

I am not an HCP

I am an HCP

Leaving almiralldermatologycongress.com

Dear User,

You are about to leave almiralldermatologycongress.com since your request does not correspond to Almirall’s content related to EADV Congress 2024.

We will redirect you to almirall.com

Thanks for your visit.

Come back soon!

Leave

Stay

Prof. Dirschka

Germany

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Thomas Dirschka graduated in medicine at the University of Bochum, Germany in 1993 and has since specialised in dermatology. After a period of research at the Medical College of Virginia in the USA, Professor Dirschka returned to Germany and did further research work before entering private dermatological practice.

His areas of special interest include prevention and treatment of skin cancer, inflammatory skin diseases, allergy,dermatopathology, and aesthetic dermatology.

He is actively involved in clinical study programmes and clinical trials to determine the efficacy and safety of novel treatments for dermatological conditions. In 2000 Professor Dirschka founded CentroDerm®, a company for research and development in the field of dermatology. In this context he runs a skin physiology laboratory for investigation of skin barrier function, skin sensitivity and effects of topical applications on the skin.

Prof. Fargnoli

Italy

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Maria Concetta Fargnoli is Full Professor of Dermatology and Chair of the Department of Dermatology at the University of L’Aquila, Italy. She received her medical degree in 1992 at the University of Rome “Tor Vergata”, completed her residency in Dermatology and Venereology at the University of L’Aquila in 1998 and started her academic career in 1999. She is the Director of the Laboratory of Molecular Biology in Dermato-Oncology, Director of the Interdepartmental Centre of Molecular Diagnostics and Advanced Therapies, Faculty of the PhD Program in Experimental Medicine at the University of L’Aquila and Coordinator of the Skin Cancer Tumor Board.

Her clinical and experimental research interests include epidemiology and molecular genetics of melanoma and non-melanoma skin cancers, non-invasive diagnostic techniques in dermatology, new therapeutic interventions for inflammatory and neoplastic skin diseases. She is actively involved in conducting clinical trials primarily focusing on non-melanoma skin cancers, psoriasis, atopic dermatitis and prurigo nodularis.

She has published 265 peer-reviewed scientific papers, contributed to many book chapters and lectured at national and international meetings. Prof. Fargnoli acts as reviewer of international journals on dermatology, oncology and genetics.

Prof. Fargnoli is currently VicePresident of the Italian Society of Dermatology (SIDeMaST) and has been board member, secretary, coordinator of the Group of Experimental Research and Bioengeneering in Dermatology and coordinator of the Scientific Committee of SIDeMaST.

Dr. Boada

Spain

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Dr. Aram Boada (Barcelona, 1979) is a specialist in Dermatology and Venereology (2008) and PhD degree from the Universitat Autònoma de Barcelona (2020). He works as Section Chief and Melanoma Unit Coordinator of the Dermatology Department of Hospital Universitari Germans Trias i Pujol in Badalona (Barcelona, Spain). His main fields of research are Dermato-Oncology (melanoma, field cancerization and cutaneous toxicities of oncologic treatments) with more than 100 publications and conference communications.